Qiagen (NYSE:QGEN) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of Qiagen (NYSE:QGEN - Free Report) to a hold rating in a report released on Thursday morning, Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird lifted their target price on shares of Qiagen from $49.00 to $52.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Wolfe Research raised shares of Qiagen from a "peer perform" rating to an "outperform" rating and set a $50.00 target price on the stock in a report on Thursday, June 27th. Finally, HSBC cut shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Qiagen presently has a consensus rating of "Moderate Buy" and a consensus price target of $50.12.

Qiagen Stock Up 0.7 %

Shares of NYSE:QGEN traded up $0.30 during trading on Thursday, hitting $43.00. 1,022,230 shares of the company were exchanged, compared to its average volume of 1,194,124. The stock has a market capitalization of $9.81 billion, a P/E ratio of 142.05, a PEG ratio of 3.36 and a beta of 0.39. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. Qiagen has a 12-month low of $34.74 and a 12-month high of $47.44. The firm's 50 day moving average price is $45.14 and its 200-day moving average price is $43.51.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The company's revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.53 EPS. On average, research analysts predict that Qiagen will post 2.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Qiagen by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company's stock worth $382,856,000 after purchasing an additional 83,371 shares during the period. Nuance Investments LLC grew its stake in shares of Qiagen by 17.3% during the 2nd quarter. Nuance Investments LLC now owns 5,271,494 shares of the company's stock worth $216,606,000 after purchasing an additional 778,005 shares during the period. Earnest Partners LLC grew its stake in shares of Qiagen by 11.1% during the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company's stock worth $156,441,000 after purchasing an additional 379,679 shares during the period. DekaBank Deutsche Girozentrale grew its stake in shares of Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company's stock worth $133,292,000 after purchasing an additional 353,280 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Qiagen by 18.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,995,671 shares of the company's stock worth $82,002,000 after purchasing an additional 305,908 shares during the period. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.